Paul Collini
Impact in
- Infectious Diseases top 0.5%
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 detection and testing
-
- Antibiotic Use and Resistance
Papers in
-
- SARS-CoV-2 and COVID-19 Research 13
- COVID-19 Clinical Research Studies 11
- HIV/AIDS Research and Interventions 4
- Tuberculosis Research and Epidemiology 3
- Epidemiology 19
- Pneumocystis jirovecii pneumonia detection and treatment 7
- Pneumonia and Respiratory Infections 3
- Co-authors
- David Harold Dockrell (9 shared papers)Ed J. Kuijper (2 shared papers)Martijn P. Bauer (1 shared paper)Robert T. Miller (3 shared papers)Mahdad Noursadeghi (2 shared papers)Martin A. Bewley (2 shared papers)Ian Sabroe (1 shared paper)Alison M. Morris (1 shared paper)
- Journals
- The Lancet (7 papers)American Journal of Respiratory and Critical Care Medicine (3 papers)The Lancet Respiratory Medicine (3 papers)Wellcome Open Research (3 papers)Journal of Infection (3 papers)
- Partner nations
- United KingdomUnited StatesAustralia
In The Last Decade
Paul Collini
74 papers receiving 5.1k citations
Paul Collini's Hit Papers
Peers
Comparison fields: 5 of 142
- Infectious Diseases 3.0k
- Applied Microbiology and Biotechnology 182
- Neurology 749
- Critical Care and Intensive Care Medicine 165
- Modeling and Simulation 112
Countries citing papers authored by Paul Collini
This map shows the geographic impact of Paul Collini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Collini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Collini more than expected).
Fields of papers citing papers by Paul Collini
This network shows the impact of papers produced by Paul Collini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Collini. The network helps show where Paul Collini may publish in the future.
Co-authors
The 25 scholars most cited alongside Paul Collini, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 76 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses Hit paper breakdown → | 2022 | 740 |
| 2 | Mapping the human genetic architecture of COVID-19 Hit paper breakdown → | 2021 | 641 |
| 3 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 4 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 5 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 6 | 2020 | 260 | |
| 7 | Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study Hit paper breakdown → | 2021 | 249 |
| 8 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 230 |
| 9 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 10 | 2021 | 161 | |
| 11 | 2021 | 160 | |
| 12 | 2021 | 135 | |
| 13 | 2021 | 119 | |
| 14 | 2022 | 86 | |
| 15 | 2023 | 83 | |
| 16 | 2017 | 82 | |
| 17 | 2021 | 75 | |
| 18 | 2021 | 68 | |
| 19 | Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease Hit paper breakdown → | 2024 | 65 |
| 20 | 2018 | 61 |
About Paul Collini
Paul Collini is a scholar working on Infectious Diseases, Epidemiology, Neurology, Virology and Applied Microbiology and Biotechnology, having authored 76 papers that have together received 5.3k indexed citations. Recurring topics across this work include SARS-CoV-2 and COVID-19 Research (13 papers), COVID-19 Clinical Research Studies (11 papers), Pneumocystis jirovecii pneumonia detection and treatment (7 papers), Long-Term Effects of COVID-19 (6 papers), HIV/AIDS Research and Interventions (4 papers), COVID-19 epidemiological studies (3 papers), Tuberculosis Research and Epidemiology (3 papers) and Pneumonia and Respiratory Infections (3 papers). The work is most often cited by research in Infectious Diseases (3.0k citations), Applied Microbiology and Biotechnology (182 citations), Neurology (749 citations), Critical Care and Intensive Care Medicine (165 citations) and Modeling and Simulation (112 citations). Paul Collini has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include David Harold Dockrell, Ed J. Kuijper, Martijn P. Bauer, Robert T. Miller, Mahdad Noursadeghi, Martin A. Bewley, Ian Sabroe, Alison M. Morris, Helen M. Marriott and Fiona Pearce. Their work appears in journals such as The Lancet, American Journal of Respiratory and Critical Care Medicine, The Lancet Respiratory Medicine, Wellcome Open Research and Journal of Infection.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.